2 Hrs
Source:
Sharjah24
Emirates Pharma approves Rinfok for vitiligo
The Emirates Pharmacеutical Establishment announced the approval of the use of "Renfoc" (Obudasetinib) for the treatment of non-segmental vitiligo in adults and adolescents aged 12 and above, making it the first orally licensed treatment for this use worldwide. The medication is administered once daily by mouth and aims to improve treatment options for patients whose condition requires systemic therapy, while supporting the UAE's position in keeping pace with pharmaceutical innovations and providing advanced treatment options.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)